CXCL9 and pneumonitis: This entails the development of predictive biomarkers, such as dynamic changes in circulating cytokines (e.g., T-cell recruiting CXCL9/10 versus pro-inflammatory IL-6/IL-8) and the peripheral T-cell repertoire diversity, to stratify patients for benefit and pneumonitis risk (22, 23).